RecruitingNot ApplicableNCT02290834
Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer
Sponsor
Massachusetts General Hospital
Enrollment
200 participants
Start Date
Mar 1, 2015
Study Type
INTERVENTIONAL
Conditions
Summary
This research study evaluates the effect of chemotherapy on cognition (thinking) and the brain in people with breast cancer.
Eligibility
Sex: FEMALEMin Age: 60 Years
Plain Language Summary
Simplified for easier understanding
This trial is studying how chemotherapy affects thinking, memory, and brain structure in older women with breast cancer, to better understand and manage what is sometimes called 'chemo brain.'
**You may be eligible if...**
- You are a woman aged 60 or older
- You have a new diagnosis of invasive breast cancer
- Your treatment plan includes chemotherapy
- Your life expectancy is at least 1 year
- Your general health score (Karnofsky) is 80 or above
- You are able to understand and complete questionnaires in English
**You may NOT be eligible if...**
- You have a prior history of cancer (other than certain skin or cervical cancers)
- You have a known neurological condition affecting memory or thinking
- You have significant hearing or vision loss that would affect testing
- You are already receiving cancer treatment
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERCognitive, functional and subjective assessments
Cognitive and functional assessments
DEVICEMRI
Magnetic Resonance Imaging (MRI) Scan
RADIATIONPET Scan
Positron Emission Tomography (PET) Scan
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02290834
Related Trials
Utility of a Mobile Application for Young Women With Breast Cancer
NCT070090931 location
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
NCT0710010645 locations
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
NCT028307241 location
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT07085767150 locations
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
NCT0740580145 locations